Visium Asset Management Reports 5.5% New Stake In OHR Pharmaceutical Inc (OHRP)

Jacob Gottlieb thinks OHR Pharmaceutical Inc (NASDAQ:OHRP) is a good investment and has initiated a new position for his fund, Visium Asset Management. According to a recent filing with the Securities and Exchange Commission, Gottlieb and Visium have acquired 1.22 million shares, amassing 5.2% of the company’s common stock.

OHR Pharmaceutical Inc

Both Cliff Asness and Israel Englander have become fans of OHR Pharmaceutical Inc (NASDAQ:OHRP) and have initiated positions for their respective funds. Englander’s Millennium Management has acquired a little over 900,000 shares during the first quarter of 2014, as reported in the fund’s latest 13F filing. The position built by Asness during the same period for AQR Capital Management is much smaller – 13,100 shares. Geoffrey Raynor is also bullish on OHR Pharmaceutical Inc (NASDAQ:OHRP) and has acquired approximately 57,600 shares for his fund, Q Investments (Specter Holdings), according to its latest 13F filing.

Disclosure: none.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!